author-photo

Stephane Giraudier

Paris 12 Val de Marne University

13

Papers

59

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)
GATA 1: pArg202Thr, a New GATA 1 Mutation Involved in a Severe Dyserythropoietic Phenotype

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

2014 Blood
Show All
- Source
- Cite
- Save
Citations (27)
Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Long Term Efficacy and Tolerance of Pegylated Interferon Alpha Therapy for Patients with High Risk Essential Thrombocythemia: An Observational Study of the French Intergroup of Myeloproliferative Disorders (FIM)

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)
(MDS) on anemia, costs and quality of life: a randomized controlled trial factor (rHuG-CSF) for the treatment of myelodysplastic syndromes Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating

2013
Show All
- Source
- Cite
- Save
Citations (0)
myelodysplastic syndromes: a randomized, controlled trial granulocyte colony-stimulating factor for the treatment of Health, economic, and quality-of-life effects of erythropoietin and

2013
Show All
- Source
- Cite
- Save
Citations (0)
Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia

2013 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia

2013 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (17)
Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score

2013 Blood
Show All
- Source
- Cite
- Save
Citations (2)